Patients Treated for Common Cancers in Community Settings Live Longer, COA Study Finds

Why It Matters

The findings validate community oncology as a high‑quality, outcomes‑driven care model, influencing payer contracts, policy decisions, and patient choice amid ongoing regulatory and reimbursement pressures.

Key Takeaways

• Community sites show 8‑month breast cancer survival advantage over SEER.
• NSCLC patients gain 2‑month median survival benefit in community settings.
• Study spans 98,000 stage IV cases from 2013‑2022.
• Adjusted data: 46 vs 29 months breast, 12 vs 6 months NSCLC.
• Personal touch and rapid therapy adoption drive community advantage.

Pulse Analysis

Community oncology has long argued that proximity and personalized service can match or exceed the outcomes of academic centers, but hard data were scarce. The new COA‑backed analysis, leveraging Flatiron Health’s real‑world electronic health record repository and the SEER cancer registry, provides the first large‑scale survival comparison. By standardizing demographics and employing propensity‑score weighting, the study isolates treatment setting as a key variable, revealing that patients receiving care at community practices live significantly longer for two of the most common metastatic cancers.

The survival advantage is most pronounced in metastatic breast cancer, where median overall survival reached 48 months—an eight‑month gain over SEER’s benchmark. When the cohort was adjusted to mirror SEER’s demographic profile, the gap widened to 46 versus 29 months, underscoring the robustness of the finding. For metastatic NSCLC, community patients saw a two‑month median benefit, expanding to a six‑month lead after adjustment. Sub‑analyses suggest that rapid adoption of targeted therapies in hormone‑positive and HER2‑positive breast cancers drives much of the edge, while triple‑negative disease remains a shared challenge.

Beyond the clinical numbers, the study reshapes the business narrative for community oncology. Payers and policymakers now have evidence that decentralized care can deliver superior outcomes while reducing travel burdens and hospitalizations. This may accelerate value‑based contracting, support reimbursement parity, and encourage investment in supportive services such as navigation and tele‑oncology. The COA plans further phases examining CAR‑T, radioligand therapies, and additional tumor types, signaling a broader research agenda that could cement community practices as innovation hubs within the U.S. cancer care ecosystem.